BIOGEN INC. (BIIB) FY2024 Annual P&L / Income Statement

BIOGEN INC. (BIIB) FY2024 Annual P&L / Income Statement

Income statement for 2024-01-01 through 2024-12-31. View: Product and service (Revenues by Product). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

9,675,900,000 US dollars

Cost of sales, excluding amortization and impairment of acquired intangible assets

2,310,400,000 US dollars

Gross profit (calculated)

7,365,500,000 US dollars

Operating expenses (calculated)

5,459,500,000 US dollars

Operating profit (calculated)

1,906,000,000 US dollars

Other income (expense), net (calculated)

0 US dollars

Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax

1,906,000,000 US dollars

Income tax (benefit) expense

273,800,000 US dollars

Net income

1,632,200,000 US dollars

BENEPALI

479,100,000 US dollars

IMRALDI

213,100,000 US dollars

FLIXABI

63,200,000 US dollars

BYOOVIZ

36,600,000 US dollars

TOFIDENCE

1,100,000 US dollars

TECFIDERA

967,100,000 US dollars

VUMERITY

628,000,000 US dollars

AVONEX

707,500,000 US dollars

PLEGRIDY

260,500,000 US dollars

TYSABRI product

1,715,000,000 US dollars

FAMPYRA

71,700,000 US dollars

ZURZUVAE

72,200,000 US dollars

FUMADERM And ADUHELM

10,300,000 US dollars

SPINRAZA

1,573,200,000 US dollars

QALSODY

32,400,000 US dollars

SKYCLARYS

382,500,000 US dollars

Alzheimer's collaboration revenue

59,900,000 US dollars

Contract manufacturing, royalty and other revenue

652,600,000 US dollars

Revenue from anti-CD20 therapeutic programs

1,749,900,000 US dollars

Research and development

2,041,800,000 US dollars

Selling, general and administrative

2,403,700,000 US dollars

Amortization and impairment of acquired intangible assets

446,700,000 US dollars

Gain on sale of priority review voucher, net

negative 88,600,000 US dollars

Collaboration profit sharing/(loss reimbursement)

254,400,000 US dollars

Gain on sale of building, net

0 US dollars

Other (income) expense, net

343,600,000 US dollars

(Gain) loss on fair value remeasurement of contingent consideration

27,700,000 US dollars

Restructuring charges

30,200,000 US dollars

Equity in (income) loss of investee, net of tax

0 US dollars. Reported below-tax contribution to net income.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.